GDC-0834

Overview

GDC-0834 is an orally active selective, potent, and reversible BTK inhibitor with an IC 50 of 5.9 nM. GDC-0834 demonstrates pBTK-Tyr223 inhibition in mice and rats. GDC-0834 can be used for research of rheumatoid arthritis (RA).

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-15427
• CAS No.: 1133432-49-1
• Molecular Formula: C33H36N6O3S
• Molecular Weight: 596.74
• Purity: 98.05%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Availability: In-stock

Source

Original product source